ESElena N. Simonova

Elena N. Simonova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena N. Simonova has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Baricitinib in rheumatoid arthritis in real-world clinical practice: pooled analysis of the overall patient cohort and a subgroup of patients with difficult-to-treat disease according to the Moscow registry

    by Yu. A. Gavrikova, V. V. Dolgov, E. N. Simonova, A. I. Zagrebneva

    Baricitinib (BARI) is widely used in rheumatoid arthritis (RA); however, real-world data on its place in therapy and efficacy in patients with difficult-to-treat (D2T) RA are limited. Objective: to assess the clinical and demographic characteristics of patients with RA, including those in the D2T RA subgroup, the outcomes of BARI use in routine practice across different lines of therapy (LT) and switching strategies, as well as its steroid-sparing effect. Material and methods. A retrospective analysis was performed of patients included in the Moscow registry of immune-mediated inflammatory/autoimmune diseases who were followed up from 19.08.2021 to 26.12.2024 and were prescribed BARI. Data from three visits (V1–V3) with a 6-month interval were analyzed. Study endpoints were changes in DAS28-ESR/CRP, CDAI/SDAI, tender joint count (TJC) and swollen joint count (SJC), patient and physician global assessment of disease activity; the proportion of patients in remission and with low disease activity; the number of patients receiving glucocorticoids (GCs) and methotrexate (MTX), as well as GCs and MTX doses. Current therapy at the time of the study and prior therapy were analyzed; a separate analysis was performed for the D2T RA subgroup. Results and discussion. The study included 188 patients (82% women); mean age was 56.0±12.1 years; median RA duration was 11 (7–18) years. The mean follow-up duration was 12.6 (2.3–29.7) months. The intervals between visits averaged 6.5 months. The D2T RA subgroup included 17 (9%) patients. BARI was prescribed as 1st LT in 62.2% of patients, as 2nd LT in 14.9%, and as 3rd LT in 22.9%; 62.2% of patients had not previously received biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs), whereas 37.8% were switched to BARI from bDMARDs or tsDMARDs. By V3, with BARI used as 1st LT, the median DAS28-ESR decreased from 3.4 to 3.1 (-8.8%; pnd LT, from 3.3 to 2.9 (-12.1%); and as 3rd LT, from 4.1 to 2.9 (-29.3%); the median DAS28-CRP decreased by 6.9%, 6.9%, and 24.1%, respectively. The greatest reduction in activity indices was observed after switching from interleukin-6 inhibitors (IL-6i): the median DAS28-ESR decreased from 4.02 to 2.99 (-25.6%; p=0.0174) and CDAI from 14.47 to 10.88 (-24.8%). The smallest decrease in indices was recorded after prior therapy with Janus kinase inhibitors (JAKi). In such patients, DAS28-ESR decreased on average by 3.0%, while CDAI increased by 9.1%. In the D2T RA group, a significant reduction in SJC (-74.1%) and TJC (-59.6%) was noted (pConclusion. In real-world practice, BARI therapy provided a reduction in RA activity across different LT and demonstrated a steroid-sparing effect. Even in patients with D2T RA, a clinically meaningful decrease in arthritis activity was observed. The most favorable switching outcomes were noted in patients previously treated with IL-6i, whereas in patients who had used JAKi, the effect of BARI was limited, which is associated with a change in the mechanism of action when another drug is prescribed. These findings require confirmation in prospective studies.

  • Therapeutic targets of disease-modifying therapy for secondary osteoarthritis (DMOADs): a systematic review

    by O. A. Gromova, A. I. Zagrebneva, I. V. Sarvilina, O. A. Shavlovskaya, I. Yu. Torshin, E. N. Simonova

    Secondary osteoarthritis (OA) may develop in the setting of various diseases and injuries of the joints, including rheumatoid arthritis (RA), psoriasis (psoriatic arthritis, PsA), and ankylosing spondylitis (AS). This article presents a systematic review of highly purified standardized drugs of chondroitin sulfate (CS) and glucosamine sulfate (GS) used in the treatment of secondary OA in various models of RA, PsA, and AS. The molecular links of targeting the pathogenesis of secondary OA are considered in specific detail. CS and GS are shown to inhibit hyperinflammation through the CD44 and TLR2/4/8 receptors, as well as the NF-κB transcription factor, thus acting as a disease-modifying therapy for RA, PsA, and AS. Experimental and clinical studies of the effects of CS and GS in RA, PsA, and AS have confirmed the prospects of their standardized forms for use in the treatment and prevention of the diseases under consideration.

  • Open Access

    High efficacy and retention rate of levilimab in the treatment of patients with rheumatoid arthritis in real-life practice

    by A. I. Zagrebneva, E. N. Simonova, Yu. A. Gavrikova, V. V. Dolgov, G. A. Togizbayev

    Previously published results of a retrospective analysis showed that switching to levilimab from other interleukin 6 receptor inhibitor (iIL6R) allows maintaining the achieved effect, and in some cases, increasing the effectiveness of treatment. This article presents the results of an extended observation period.The aim – to evaluate the efficacy, safety and retention rate of levilimab in patients with rheumatoid arthritis (RA) during one year of observation.Materials and methods. A retrospective analysis of data from the Moscow register of RA patients. The analyzed sample included RA patients who received levilimab 162 mg weekly after switching from other iIL6R (tocilizumab and sarilumab). Patient retention rate on levilimab therapy was assessed during 52 weeks of observation. The efficacy was evaluated at months 3, 6, 9 and 12 of levilimab therapy by the following parameters: laboratory markers of inflammation (C-reactive protein (CRP), erythrocyte sedimentation rate), assessment of the number of swollen (SJC) and painful (PJC) joints, assessment of the patient’s global assessment (PGA) by visual analogue scale (VAS), and DAS28-CRP (Disease Activity Score 28 with CPR).Results. 141 patients were included in analysis, the majority of patients were female (89%), the mean age was 57.8 years. The mean duration of levilimab therapy was 12.2±4.4 months. After 12 months of treatment, 87.5% [95% confidence interval: 82.1; 93.2] of patients continued levilimab therapy. Retention rate of levilimab therapy remained high in the levilimab monotherapy and combination therapy subgroups, and when prescribed as second or following biologic disease-modifying antirheumatic drugs (DMARDs). The mean DAS28-CRP, CRP level, TJC, SJC, and PGA by VAS were low at the time of initiation of levilimab therapy and remained stable during the year of therapy.Conclusions. Levilimab had high patient retention in therapy when used both as monotherapy and in combination with conventional synthetic DMARDs, as well as when prescribed in second and following lines of biologic DMARDs.


  • Moscow experience of using etanercept biosimilar in patients with immune-inflammatory rheumatic diseases

    by Alena I. Zagrebneva, Elena N. Simonova, Тatiana V. Mezenova, Natalia B. Burmistrova, Yuliya A. Gavrikova, Vladislav V. Dolgov, Evgeniya O. Morozova, Zhaneta M. Kodzeva, Ksenia S. Sapogina, Anastasia A. Fomina

    The growing demand for biological disease-modifying antirheumatic drugs (bDMARDs) and their high cost put a heavy burden on the healthcare budget, thereby limiting the availability of treatment for patients. The introduction of bDMARDs biosimilars into clinical practice has made it possible to expand the availability of therapy for a larger number of patients. Our analysis of the use of the biosimilar etanercept Erelzi in 103 patients with rheumatoid arthritis showed that the drug is highly effective in the treatment of rheumatoid arthritis. It can be used both in bionaive patients with the ineffectiveness of basic therapy, and in the case of medical switching from other biologics (including tumor necrosis factor alpha inhibitors (iTNF)) and targeted synthetic basic anti-inflammatory drugs (tsDMARDs), as well as when non-medical switching is necessary. The biosimilar of etanercept Erelzi has optimal cost of treatment course and the lowest cost-effectiveness value, which means that its use will not affect the budget and will make highly effective therapy available to more patients.

  • Open Access

    Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience

    by A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, E. O. Morozova, Zh. M. Kodzeva, K. S. Sapogina, В. В. Долгов

    Objective: to confirm the efficacy and safety of levilimab in patients with rheumatoid arthritis (RA) switched from other interleukin 6 receptor inhibitors (iIL6R) for non-medical reasons.Patients and methods. A retrospective analysis of data from the register of patients with RA who during the COVID-19 pandemic were switched from foreign iIL6Rs to the Russian drug levilimab. Treatment regimens with levilimab in combination with synthetic diseasemodifying antirheumatic drugs (sDMARDs) and/or glucocorticoids (GCs) were used, as well as a monotherapy regimen in case of DMARDs intolerance.Results and discussion. In 150 patients with RA, a successful non-medical switch to levilimab was demonstrated with the preservation and intensification of the clinical effect achieved on previous therapy with iIL6R. After switching to levilimab, the DAS28-CRP index decreased by an average of 0.098 at 3 months and by 0.25 at 6 months (p=0.214 for both time points). There was a decrease in the proportion of patients with elevated levels of CRP, as well as with high RA activity. In a number of patients who showed high efficacy of levilimab, it became possible to reduce the dose or number of DMARDs, as well as cease GCs intake. Good tolerability and a favorable safety profile of levilimab were noted, including in relation to the new coronavirus infection that developed during therapy.Conclusion. Therapy with Russian iIL6R levilimab is effective and safe, including in patients switched from other drugs for non-medical reasons, as well as in relation to the novel coronavirus infection that developed during therapy.


  • Open Access

    Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment

    by Alexey I. Khripun, Andrey V. Starshinin, Yulia O. Antipova, Mariana A. Lysenko, Yulia V. Urozhaeva, Olga F. Gavrilenko, Natalya A. Rusantsova, Andrei A. Tyazhelnikov, Elena Yu. Tikhonovskaya, Natalia V. Okolot, et al.

    Aim. To study the effect of levilimab or baricitinib in combination with standard therapy (ST) on the incidence of severe viral pneumonia associated with a new coronavirus infection COVID-19. Materials and methods. A multicenter, open-label observational study of the efficacy and safety of levilimab in combination with ST (group 1, n=100), baricitinib in combination with ST (group 2, n=139), or in comparison with ST (group 3, n=200) in outpatients with verified CT-1 pneumonia. Results. According to the results of laboratory tests, patients treated with levilimab in combination with ST had the best dynamics of changes in CRP from reliably the highest level (mg/L) to the lowest in comparison with other groups. In the group of patients with ST, in contrast to the other groups, no dynamics of CRP was observed by day 5 of therapy. In group of hospitalized patients initially receiving levilimab in addition to ST, the rate of transfer to the intensive care unit (2 patients, 9.52%) and length of stay (4 days) was significantly lower compared to the values in patients in both the baricitinib group in combination with ST (7 patients, 15.56%; 5 days [interquartile range 36.5]) and in patients receiving ST alone (7 patients, 15.56%; 5 days [interquartile range 36.5]). Also in hospitalized patients we observed no statistically significant intergroup differences in the incidence of infectious complications and thromboembolic events, which confirms the safety of including levilimab or baricitinib in COVID-19 pathogenetic therapy regimens. Observational results support the hypothesis that the initial inclusion of levilimab or baricitinib in addition to ST is accompanied by a reduced risk of viral pneumonia progression. Conclusion. The addition of levilimab or baricitinib to the therapy regimen for coronavirus infection during the outpatient phase has demonstrated a preemptive anti-inflammatory effect and reduced the probability of lung tissue damage progression.